TSHA Taysha Gene Therapies Inc
Price (delayed)
$1.32
Market cap
$270.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$190.27M
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to
Highlights
Taysha Gene Therapies's quick ratio has increased by 35% YoY
Taysha Gene Therapies's net income has increased by 20% YoY
Taysha Gene Therapies's EPS has shrunk by 157% QoQ but it has surged by 63% YoY
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
The gross profit has decreased by 46% YoY and by 16% QoQ
Key stats
What are the main financial stats of TSHA
Market
Valuations
Earnings
Shares outstanding
205M
Market cap
$270.6M
Enterprise value
$190.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.78
Price to sales (P/S)
39.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.83
Revenue
$8.33M
Gross profit
$8.33M
Operating income
-$91.46M
Net income
-$89.3M
EBIT
-$89.2M
EBITDA
-$86.73M
Free cash flow
-$81.6M
Per share
Balance sheet
Liquidity
EPS
-$0.36
EPS diluted
-$0.36
Free cash flow per share
-$0.33
Book value per share
$0.35
Revenue per share
$0.03
TBVPS
$0.64
Total assets
$160.36M
Total liabilities
$88.84M
Debt
$61.3M
Equity
$71.53M
Working capital
$115.9M
Debt to equity
0.86
Current ratio
5.42
Quick ratio
5.4
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
-1,040.8%
Gross margin
100%
Net margin
-1,071.6%
Operating margin
-1,097.6%
Return on assets
-51.5%
Return on equity
-110.6%
Return on invested capital
-179.5%
Return on capital employed
-66.5%
Return on sales
-1,070.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TSHA stock price
How has the Taysha Gene Therapies stock price performed over time
Intraday
4.35%
1 week
-26.67%
1 month
-17.5%
1 year
-51.29%
YTD
-23.7%
QTD
-5.04%
Financial performance
How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$8.33M
Gross profit
$8.33M
Operating income
-$91.46M
Net income
-$89.3M
Gross margin
100%
Net margin
-1,071.6%
TSHA's operating margin has shrunk by 134% YoY and by 24% QoQ
The net margin has contracted by 48% YoY
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
The gross profit has decreased by 46% YoY and by 16% QoQ
Growth
What is Taysha Gene Therapies's growth rate over time
Valuation
What is Taysha Gene Therapies stock price valuation
P/E
N/A
P/B
3.78
P/S
39.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.83
Taysha Gene Therapies's EPS has shrunk by 157% QoQ but it has surged by 63% YoY
TSHA's price to book (P/B) is 39% lower than its last 4 quarters average of 5.9
The company's equity fell by 19% QoQ and by 4.6% YoY
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
TSHA's price to sales (P/S) is 22% less than its last 4 quarters average of 48.4
Efficiency
How efficient is Taysha Gene Therapies business performance
The return on invested capital has surged by 85% year-on-year
Taysha Gene Therapies's return on sales has shrunk by 55% YoY
Taysha Gene Therapies's return on assets has increased by 36% YoY
Dividends
What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TSHA.
Financial health
How did Taysha Gene Therapies financials performed over time
The company's total assets is 81% higher than its total liabilities
Taysha Gene Therapies's quick ratio has increased by 35% YoY
The current ratio is up by 33% year-on-year
The debt is 14% less than the equity
Taysha Gene Therapies's debt to equity has increased by 26% QoQ and by 9% YoY
The company's equity fell by 19% QoQ and by 4.6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.